Safety, Tolerability, PK and PD of SCH 900518 in Naive or Treatment-Experienced Subjects Infected With HCV Genotype 1 (Protocol No. P04695)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT01081158
First received: March 3, 2010
Last updated: March 7, 2014
Last verified: March 2014
  Purpose

Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SCH 900518 in Naive or Treatment-Experienced Subjects Infected With Hepatitis C Virus Genotype 1 (Protocol No. P04695)


Condition Intervention Phase
Hepatitis C, Chronic
Drug: Drug: SCH 900518 Biologic: Peginterferon alfa-2b(PegIntron)
Drug: Drug: SCH 900518 Biologic: Peginterferon alfa-2b
Drug: Drug: SCH 900518 Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)
Drug: Drug: SCH 900518 Drug: Ritonavir (RTV) Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Assessment of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SCH 900518 in Naive or Treatment-Experienced Subjects Infected With Hepatitis C Virus Genotype 1 (Protocol No. P04695)

Resource links provided by NLM:


Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • Safety and tolerability were to be assessed by collecting adverse events (AEs), vital signs, electrocardiograms (ECGs), physical examinations, urinalysis, and safety laboratory tests. [ Time Frame: Screening Period: 90 days, Period 1: 7 days, Washout: 4 weeks, Period 2: 14 days, Standard of Care with PegIntron and ribavirin: 84 days ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Log change in HCV-RNA from baseline. Ctrough of SCH 900518 resulting in mean HCV RNA decrease > 2 log10 IU/mL. Ctrough of SCH 900518+PEG resulting in HCV-RNA < LOQ. SCH 900518 PK: Cmax, Tmax, AUC, Ctrough, t½, R, CL/F, Vd/F. PEG and RTV: Ctrough [ Time Frame: Period 1: 7 days, Washout: 4 weeks, Period 2: 14 Days ] [ Designated as safety issue: No ]

Enrollment: 41
Study Start Date: July 2007
Study Completion Date: August 2008
Primary Completion Date: August 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment-naïve 800 mg TID

Period 1: SCH 900518 (800 mg TID) or placebo for 7 days

Period 2: SCH 900518 (800 mg TID) + PegIntron (1.5 µg/kg QW) or placebo + PegIntron for 14 days.

Drug: Drug: SCH 900518 Biologic: Peginterferon alfa-2b(PegIntron)

Drug: SCH 900518

Biologic: Peginterferon alfa-2b(PegIntron)

Period 1: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 7 days .

Period 2: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 14 days in combination with 1.5 µg/kg PegIntron administered subcutaneously weekly.

Other Name: narlaprevir, PegIntron
Experimental: Treatment-experienced: 800 mg TID

Period 1: SCH 900518 (800 mg TID) or placebo for 7 days

Period 2: SCH 900518 (800 mg TID) + PegIntron (1.5 ug/kg QW) or placebo + PegIntron for 14 days

Drug: Drug: SCH 900518 Biologic: Peginterferon alfa-2b

Drug: SCH 900518

Biologic: Peginterferon alfa-2b

Period 1: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 7 days

Period 2: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 14 days in combination with 1.5 µg/kg PegIntron administered subcutaneously weekly.

Other Name: narlaprevir, PegIntron
Experimental: Treatment-naïve: 400 mg + RTV BID

Period 1: SCH 900518 (400 mg BID) or placebo + RTV (200 mg BID) for 7 days.

Period 2: SCH 900518 (400 mg BID) or placebo + RTV (200 mg BID) +PegIntron (1.5 µg/kg QW) for 14 days.

Drug: Drug: SCH 900518 Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)

Drug: SCH 900518

Drug: Ritonavir (RTV)

Biologic: Peginterferon alfa-2b (PegIntron)

Period 1: Amorphous SCH 900518 (400 mg) or placebo BID administered as oral suspension + ritonavir (200 mg BID) (2-100 mg oral capsules) for 7 days.

Period 2: Amorphous SCH 900518 (400 mg) or placebo BID administered as oral suspension+ ritonavir (200 mg BID) (2-100 mg oral capsules) + PegIntron (1.5 µg/kg QW) for 14 days.

Other Name: narlaprevir, norvir, PegIntron
Experimental: Treatment-experienced: 400 mg + RTV BID

Period 1: SCH 900518 (400 mg BID) or placebo + RTV (200 mg BID) for 7 days.

Period 2: SCH 900518 (400 mg BID) or placebo + RTV (200 mg BID) +PegIntron (1.5 µg/kg QW) for 14 days.

Drug: Drug: SCH 900518 Drug: Ritonavir (RTV) Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)

Drug: SCH 900518

Drug: Ritonavir (RTV)

Biologic: Peginterferon alfa-2b (PegIntron)

Period 1, Amorphous SCH 900518 (400 mg) or placebo BID administered as an oral suspension + RTV (200 mg BID) oral capsules (2-100 mg capsules) for 7 days.

Period 2, SCH 900518 (400 mg) or placebo BID as an oral suspension + RTV (200 mg BID) oral capsules (2-100 mg capsules) +PegIntron (1.5 µg/kg SC QW) for 14 days.

Other Name: narlaprevir, norvir, PegIntron

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject infected with HCV genotype 1 (any sub-type) virus who is:

    • treatment naïve (eg. to interferon and ribavirin); or
    • treatment experienced (non-responder and relapser): subject who received interferon based therapy and continued to have detectable HCV RNA levels at the end of follow-up, a subject who did not attain a 2 log decline in HCV RNA levels at ~12 weeks and discontinued treatment, or subject who had no detectable viral load while on treatment but had a detectable viral load post treatment.
  • Subject with acceptable medical history, physical examination, and clinical laboratory evaluations consistent with CHC, compensated liver disease, and any associated diseases (diabetes, hypertension, etc).
  • Subjects with an HCV RNA viral load of >10^5 copies/mL or equivalent international units

BMI of 18 to 40 kg/m^2, men and women, ages 18-65 years inclusive

  • Female must be non-lactating and have a negative pregnancy test at Screening and Day -1 and either be of nonchildbearing potential or if of childbearing potential, must be practicing effective double-barrier contraceptive methods from at least 2 weeks prior to Day -1 until 30 days after study completion.
  • Male must be willing to practice barrier contraception from Day 1 through 3 months following treatment with SCH 900518.
  • Subject must have an ECG recording showing no clinically significant findings at Screening.
  • Subject with chronic stable hemophilia may enroll
  • Subject on stable methadone treatment may enroll in this study (evaluation by investigator includes history of stable clinical management for >3 months).

Exclusion Criteria:

  • Subject has a significant acute or chronic medical illness which is not stable or is not controlled with medication (excluding prohibited medications).
  • Subject has received an organ transplant.
  • Subject has evidence of decompensated liver disease by physical exam (encephalopathy, ascites, caput medusae, etc).
  • Subject has at anytime received an HCV NS3-specific protease inhibitor.
  • Subject has a platelet count <80,000/mm^3 (confirmed by repeat analysis) at Screening.
  • Subject has a serum hemoglobin of <10.0 g/dL (confirmed by repeat analysis) at Screening.
  • Subject has a serum AST /ALT value >5 x ULN (confirmed by repeat analysis) at Screening.
  • Subject has a serum alkaline phosphatase value >2 x ULN (confirmed by repeat analysis) at Screening.
  • Two or more of the following criteria (confirmed by repeat analysis) at Screening:

    • Total serum bilirubin >2.0 mg/dL.
    • Serum albumin <3.5 g/dL.
    • INR >1.7 (with the exception of hemophiliacs).
  • Subject has a neutrophil count <1,000/mm^3 (confirmed by repeat analysis) at Screening.
  • Creatinine clearance (as estimated by method of Cockcroft and Gault) less than 50 mL/min at Screening.
  • Subject who has a history of any clinically significant local or systemic infectious disease within 1 week prior to screening (other than HCV-infection).
  • Male subject whose female partner intends on becoming pregnant within 3 months of the study.
  • Subject is positive for HIV antibodies or hepatitis B surface antigen.
  • Subject has a clinically significant allergy or intolerance to foods or drugs, or is known or suspected to have hypersensitivity to any ingredient in the investigational product.
  • Subject has a clinically significant history of auto-immune hepatitis.
  • Subject has used any investigational drugs or donated blood within 30 days prior to study drug administration.
  • Subject who received any of the following treatments: known inhibitor of CYP3A4 metabolism (2 weeks of prior to randomization), known inducer of CYP3A4 metabolism (2 weeks prior to randomization) and treatment for HCV infection (1 month prior to randomization)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Publications:
Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT01081158     History of Changes
Other Study ID Numbers: P04695
Study First Received: March 3, 2010
Last Updated: March 7, 2014
Health Authority: The Netherlands: Centrale Commissie Mensgebonden Onderzoek (CCMO)

Additional relevant MeSH terms:
Hepatitis
Hepatitis A
Hepatitis C
Hepatitis C, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Hepatitis, Chronic
Ritonavir
Peginterferon alfa-2b
Interferon-alpha
HIV Protease Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses
Immunologic Factors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on October 19, 2014